Dementia with Lewy Bodies (DLB) or Parkinson’s Disease Dementia (PDD)

Dementia with Lewy Bodies (DLB) or Parkinson’s Disease Dementia (PDD)

About this clinical trial

The purpose of this study is to test a combination of two drugs called clenbuterol (CST-103) and nadolol (CST-107) which are being developed for the treatment of a collection of diseases involving deterioration of certain brain cells and nervous system, including Dementia with Lewy Bodies (DLB) and Parkinson’s Disease Dementia (PDD). 

The primary objective is to identify central nervous system signals following multiple oral doses of CST-103 in the presence of CST-107 in four populations of participants with Neurodegenerative Disorders (NDD). 

Patients Required

Estimated completion

February 2022

Total participants required

Up to 10

Study location

The Wesley Hospital

Trial title

CLIN-011– A Phase II, Randomized, Placebo-Controlled,  Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 co-administered with CST-107 on the Central Nervous System in Subjects with Neurodegenerative Disorders.


To be eligible for this trial you need to be diagnosed with Dementia with Lewy Bodies (DLB) or Parkinson’s Disease Dementia (PDD).

Additional information

You can find out more about this clinical trial by visiting the ClinicialTrials.gov website.

Lead investigator

Dr Philip Mosley

If you would like more information about this clinical trial, please complete the Dementia with Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) contact form


Wesley Medical Research

Scroll to Top